{
  "id": "remifentanil_pharmacology_001",
  "updatedAt": "2026-02-18T00:00:00Z",

  "domain": "pharmacology",
  "topicTagIds": ["opioids", "pharmacokinetics", "pharmacodynamics"],
  "caseId": null,
  "slotType": "any",
  "caseOrder": 0,

  "demographics": {
    "patientAgeGroup": "adult",
    "patientGender": "male"
  },

  "stem": "Dr. {{candidate_name}}, tell me about remifentanil.",

  "prompts": [
    {
      "tier": "recall",
      "text": "What is remifentanil and how does it differ from other opioids?",
      "expectedKeyFacts": [
        "Ultra-short-acting synthetic opioid",
        "μ-opioid receptor agonist",
        "Metabolised by non-specific plasma and tissue esterases",
        "Context-sensitive half-time remains constant (~3-4 minutes) regardless of infusion duration",
        "Inactive metabolites — no accumulation"
      ],
      "timeBudgetSec": 60
    },
    {
      "tier": "mechanism",
      "text": "Explain the pharmacokinetic properties that make remifentanil unique.",
      "expectedKeyFacts": [
        "Ester linkage rapidly hydrolysed by non-specific esterases",
        "Metabolism is independent of hepatic or renal function",
        "Small volume of distribution (~0.3 L/kg)",
        "Very high clearance (~40 mL/kg/min)",
        "Rapid redistribution and elimination",
        "No active metabolites",
        "Predictable offset even after prolonged infusion"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "application",
      "text": "A patient with severe renal failure requires a major operation. How would you use remifentanil in this context and why?",
      "expectedKeyFacts": [
        "Remifentanil is ideal for renal failure — ester metabolism is independent of renal function",
        "No dose adjustment required",
        "Avoids accumulation seen with morphine and fentanyl metabolites",
        "Predictable offset allows rapid titration",
        "Must plan alternative analgesia before discontinuation",
        "No residual analgesia after stopping infusion"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "synthesis",
      "text": "What are the potential problems when using remifentanil for anaesthesia?",
      "expectedKeyFacts": [
        "Profound bradycardia — especially with rapid bolus",
        "Chest wall rigidity at high doses",
        "Profound respiratory depression — requires mechanical ventilation",
        "Acute opioid tolerance — may require higher doses intraoperatively",
        "Hyperalgesia post-infusion — increased postoperative pain",
        "No residual analgesia — must transition to alternative analgesia before emergence",
        "Expensive compared to alternatives"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "evaluation",
      "text": "When would you choose remifentanil over fentanyl or alfentanil?",
      "expectedKeyFacts": [
        "Cases requiring rapid, predictable emergence (neurosurgery, awake craniotomy)",
        "Renal or hepatic impairment — avoids accumulation",
        "Total intravenous anaesthesia (TIVA) — stable plasma levels",
        "Cases with uncertain duration — no accumulation concern",
        "Controlled hypotension — easily titrated",
        "Acknowledge disadvantages: cost, need for transition analgesia, potential hyperalgesia",
        "Fentanyl preferred for long cases with residual analgesia requirement"
      ],
      "timeBudgetSec": 90
    }
  ],

  "rescuePrompt": "Perhaps you could tell me about the side effects of remifentanil — what do you see when you give an induction dose?",

  "keyFacts": [
    "Ultra-short-acting μ-opioid receptor agonist",
    "Metabolised by plasma and tissue esterases",
    "Context-sensitive half-time ~3-4 minutes regardless of duration",
    "Independent of hepatic and renal function",
    "No active metabolites",
    "Rapid onset and offset",
    "Bradycardia — especially with bolus",
    "Chest wall rigidity at high doses",
    "Acute tolerance and hyperalgesia",
    "No residual analgesia — requires transition plan",
    "Ideal for TIVA, neurosurgery, renal failure",
    "Expensive relative to alternatives"
  ],

  "scoringGuidance": {
    "pass": "Correctly identifies ester metabolism and esterase-mediated breakdown, explains constant context-sensitive half-time, discusses advantages in renal failure, aware of bradycardia and hyperalgesia risks, can justify choice vs other opioids; stronger candidates explain three-compartment model and transition analgesia strategies",
    "borderline": "Knows remifentanil is short-acting and metabolised differently but vague on mechanism, mentions some side effects, unclear on clinical applications or when to prefer over alternatives",
    "fail": "Cannot explain unique pharmacokinetics, unaware of ester metabolism, does not understand clinical implications of ultra-short duration, no knowledge of hyperalgesia or transition analgesia requirement"
  },

  "author": "SimViva Team",
  "provenance": {
    "generatedBy": "Claude (Anthropic)",
    "generatedAt": "2026-02-18T20:45:00Z",
    "promptVersion": "v1.0.0",
    "sourceMaterial": ["BJA_Remifentanil_Pharmacology_2018", "RCoA_Opioid_Guidelines"],
    "validation": {
      "reviewedBy": "",
      "reviewedAt": "",
      "status": "pending_review",
      "notes": "Awaiting clinical reviewer sign-off."
    }
  },
  "furtherReading": [
    "https://doi.org/10.1093/bja/aet139"
  ],
  "isActive": true
}
